Tweedy Browne Co LLC Invests $333,000 in Bristol Myers Squibb Company $BMY

Key Points

• Tweedy Browne Co LLC has invested approximately $333,000 in Bristol Myers Squibb, acquiring 7,184 shares in the biopharmaceutical company during the second quarter.
• Corporate insiders, including EVP David V. Elkins, have been actively trading their stocks, with Elkins selling 56,000 shares for over $2.6 million, representing a 25.07% decrease in their ownership.
• Bristol Myers Squibb reported earnings per share of $1.46 for the last quarter, exceeding expectations by $0.39, with a revenue of $12.27 billion.

Tweedy Browne Co LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,184 shares of the biopharmaceutical company's stock, valued at approximately $333,000.

Other large investors have also bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Bristol Myers Squibb in the first quarter worth approximately $31,000. Trifecta Capital Advisors LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter worth $25,000. Accent Capital Management LLC bought a new stake in Bristol Myers Squibb in the 1st quarter worth $33,000. CBIZ Investment Advisory Services LLC grew its holdings in Bristol Myers Squibb by 66.0% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in Bristol Myers Squibb in the 1st quarter worth $36,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.09% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on BMY shares. Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a report on Monday. Weiss Ratings reissued a "hold (c-)" rating on shares of Bristol Myers Squibb in a report on Tuesday. Dbs Bank raised shares of Bristol Myers Squibb to a "moderate buy" rating in a report on Thursday, October 2nd. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have given a Hold rating to the stock. According to MarketBeat.com, Bristol Myers Squibb currently has an average rating of "Hold" and an average price target of $57.23.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $43.37 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The company's 50-day moving average is $46.12 and its 200 day moving average is $47.66. The stock has a market capitalization of $88.28 billion, a P/E ratio of 17.49, a P/E/G ratio of 2.26 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter in the previous year, the company earned $2.07 earnings per share. Bristol Myers Squibb's quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.